Brussels is close to wrapping up preliminary talks with U.S. vaccine maker Novavax for its potential COVID-19 shot, an EU source involved in the negotiations said, as the bloc ramps up its push in the ...

U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® ...

The updated 2025-2026 COVID-19 vaccines are now widely available, but with some new limitations. Who can get the shot this ...

Novavax transfers EU rights for Nuvaxovid to Sanofi, earning milestone payments and future royalties. Read more here.

In the latest close session, Novavax (NVAX) was down 4.02% at $9.08. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 0.71%.

Novavax (NVAX) has caught the attention of investors this month, as its stock climbed over 26% in the past 30 days. The company’s performance draws curiosity about what might be fueling the move, ...

GoodRx reports that CDC now recommends COVID-19 vaccinations be decided with healthcare professionals, stressing personalized ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

There are still more than 26 million American adults who are unvaccinated. Amid growing concerns over highly contagious omicron subvariants that are spreading around the country, Americans are set to ...